Displaying drugs 1026 - 1050 of 11782 in total
Burosumab
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets .
The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved...
Approved
Investigational
Matched Description: … XLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. ... bone growth and development in children and adolescents and issues with bone mineralization throughout a ... approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a …
Didecyldimethylammonium
Approved
Experimental
Beremagene geperpavec
Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1 gene that...
Approved
Matched Description: … Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector ... [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component …
Maralixibat
Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat.[A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, patients with cholestatic pruritus associated with Alagille syndrome were treated with antihistamines, rifampin, ursodeoxycholic acid, cholestyramine, naltrexone, and...
Approved
Investigational
Matched Description: … assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a …
Exenatide
Exenatide is a glucagon-like peptide-1 (GLP-1) analog . It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control . Exenatide was given FDA approval on April 28, 2005 . It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand...
Approved
Investigational
Matched Description: … Exenatide is a glucagon-like peptide-1 (GLP-1) analog[L42690]. …
Isradipine
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity...
Approved
Investigational
Crisaborole
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Description: … Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment ... It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a ... Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center …
Tirbanibulin
Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. Actinic keratosis is a chronic condition characterized...
Approved
Investigational
Matched Description: … Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. ... into invasive squamous cell carcinoma with a risk of 1% over 10 years. ... [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform …
Nisoldipine
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone...
Approved
Matched Description: … Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. …
Ceftazidime
Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis,...
Approved
Matched Description: … Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which ... is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding ... [A232920, A232925, A232930] Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial …
Drotaverine
Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … [A231619] It is a benzylisoquinoline derivative that is structurally related to [papaverine], although …
Naldemedine
Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of DB00704 to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and...
Approved
Investigational
Matched Description: … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight …
Sodium lauryl sulfoacetate
Sodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.
Approved
Experimental
Matched Description: … Sodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products. …
Pyrantel
Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis, and trichinellosis .
Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use...
Approved
Vet approved
Matched Description: … Pyrantel has shown to be effective after a single dose [L1905]. ... Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm ... Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% …
Imatinib
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with...
Approved
Matched Description: … [A249305] It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. ... Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly ... noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a …
Sulfamethazine
A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.
Approved
Investigational
Vet approved
Matched Description: … A sulfanilamide anti-infective agent. ... It has a spectrum of antimicrobial action similar to other sulfonamides. …
Griseofulvin
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Approved
Investigational
Vet approved
Homatropine
Homatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. It is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions. Homatropine is included in subtherapeutic amounts as homatropine...
Approved
Matched Description: … Homatropine hydrobromide has been administered as ophthalmic solutions as a cycloplegic to temporarily …
Thalidomide
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha...
Approved
Investigational
Withdrawn
Matched Description: … A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn ... It has been reintroduced and used for a number of inflammatory disorders and cancers. ... activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) …
Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 10A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197). The saccharides...
Approved
Matched Description: … Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a ... antigens of *Streptococcus pneumoniae* serotype 10A individually conjugated to the CRM197 protein, a …
Guselkumab
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in...
Approved
Investigational
Matched Description: … Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin …
Sulesomab
Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Approved
Diroximel fumarate
Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS...
Approved
Investigational
Matched Description: … Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive ... [A187535]
Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing …
Displaying drugs 1026 - 1050 of 11782 in total